These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35756846)

  • 1. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
    Luong TT; Powers CN; Reinhardt BJ; Weina PJ
    Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan.
    Luong TT; McAnulty MJ; Evers DL; Reinhardt BJ; Weina PJ
    Curr Res Toxicol; 2021; 2():217-224. PubMed ID: 34345864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
    Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
    J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C; Härtter S
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P; Rochat B
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.
    Mannheimer B; Wettermark B; Lundberg M; Pettersson H; von Bahr C; Eliasson E
    Br J Clin Pharmacol; 2010 Apr; 69(4):411-7. PubMed ID: 20406225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
    Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
    BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
    Liston HL; DeVane CL; Boulton DW; Risch SC; Markowitz JS; Goldman J
    J Clin Psychopharmacol; 2002 Apr; 22(2):169-73. PubMed ID: 11910262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
    von Moltke LL; Greenblatt DJ; Court MH; Duan SX; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
    Edwards JG; Anderson I
    Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.